SCHEMBL14973000

SCHEMBL14973000

Cn1ncc(C(=O)NNC(=O)c2cccc(S(N)(=O)=O)c2)c1COc1ccc(C(F)(F)F)cn1

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MRGPRX4 Q96LA9 1/20 0.45
TLR7 Q9NYK1 3/20 0.41
SCN10A Q9Y5Y9 5/20 0.40
PTGS2 P35354 1/20 0.39
MAPT P10636 1/20 0.39
HTT P42858 1/20 0.39
NR1I2 O75469 1/20 0.38
CACNA1C Q13936 1/20 0.38
ADAMTS4 O75173 1/20 0.38
CA12 O43570 2/20 0.37
CA1 P00915 2/20 0.37
CA2 P00918 2/20 0.37
CA4 P22748 2/20 0.37
CA7 P43166 2/20 0.37
CA9 Q16790 2/20 0.37
TRPV1 Q8NER1 1/20 0.37
KAT6A Q92794 1/20 0.37
HTR2A P28223 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14973167 0.91 ADAMTS4 (0.42) MRGPRX4TLR7PTGS2MAPTADAMTS4
SCHEMBL14973349 0.90 MAPT (0.44) MRGPRX4TLR7SCN10APTGS2MAPT
SCHEMBL14973138 0.89 SIRT2 (0.37) MAPTHTTCA12CA1CA2
SCHEMBL14973113 0.84 PTGS2 (0.41) TLR7SCN10APTGS2MAPTCA12
SCHEMBL14973345 0.80 CA12 (0.46) TLR7PTGS2MAPTCA12CA1
SCHEMBL14938166 0.77 PTGDR2 (0.39) MRGPRX4ADAMTS4CA12CA1CA2
SCHEMBL14973086 0.76 MRGPRX4 (0.39) MRGPRX4PTGS2CA12CA1CA2
SCHEMBL14973083 0.75 L3MBTL1 (0.39) MAPTCA12CA1CA2CA7
SCHEMBL14973059 0.75 CA9 (0.45) MRGPRX4MAPTCA12CA1CA2
SCHEMBL14973073 0.74 CA1 (0.44) MRGPRX4CA1CA2CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2604602-A1 HETEROARYL-PYRAZOLE DERIVATIVE Taisho Pharmaceutical Co., Ltd. (JP) 2013-06-19 EP disclosed
US-20130137865-A1 HETEROARYL-PYRAZOLE DERIVATIVE TAISHO PHARMACEUTICAL CO., LTD. (JP) 2013-05-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130137865-A1 HETEROARYL-PYRAZOLE DERIVATIVE GRIN2C, GRIN2B, GRIN3A MRGPRX4 403/4885TLR7 2734/4885SCN10A 437/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.